Table 3. Characteristics of survival study participants.
| All-cause death (n=2257) | CRC death (n=1467) | Alive (n=2507) | All CRC patients (n=4764) | |
|---|---|---|---|---|
| Age at diagnosis | 71.16 (10.72) | 69.32 (10.78) | 67.04 (10.06) | 68.99 (10.58) |
| Sex | ||||
| Male | 1329 (48.47) | 838 (30.56) | 1413 (51.53) | 2742 (57.66) |
| Female | 928 (45.90) | 629 (13.20) | 1094 (54.10) | 2022 (42.44) |
| Interval between marker measurements and diagnosis (years) | 10.91 (5.17) | 11.21 (5.23) | 14.46 (5.2) | 12.78 (5.50) |
| Follow-up since diagnosis (years) | 2.98 (3.35) | 2.00 (2.12) | 6.13 (4.87) | 4.64 (4.50) |
| Period diagnosis | ||||
| <2008 | 1959 (86.80) | 1246 (84.94) | 1432 (57.12) | 3391 (77.18) |
| >2008 | 298(13.20) | 221(15.06) | 1075(42.88) | 1373(28.82) |
| TNM staging | ||||
| Tumour | ||||
| ⩽T2 | 118 (5.23) | 54 (3.68) | 588 (23.45) | 706 (14.82) |
| >T2 | 656 (29.07) | 470 (32.04) | 1112 (44.36) | 1768 (37.11) |
| Tx/unknown | 1483 (65.71) | 943 (64.28) | 807 (32.19) | 2290 (48.07) |
| Nodes | ||||
| No | 292 (12.94) | 138 (9.41) | 1051 (41.92) | 1343 (28.19) |
| Yes | 443 (19.63) | 362 (24.68) | 577 (23.02) | 1020 (21.41) |
| Nx/Missing | 1522 (67.43) | 967 (65.92) | 879 (35.06) | 2401 (50.40) |
| Metastasis | ||||
| No | 449 (19.89) | 237 (16.16) | 1204 (48.03) | 1653 (34.70) |
| Yes | 429 (19.01) | 391 (26.65) | 110 (4.39) | 539 (11.31) |
| Mx/Unknown | 1379 (61.10) | 839 (57.19) | 1193 (47.59) | 2572 (53.99) |
| Markers | ||||
| CRP (mg l−1) | ||||
| Mean (s.d.)a | 18.92 (39.60) | 18.35 (31.35) | 19.43 (38.35) | 18.92 (39.60) |
| Albumin (g l−1) | ||||
| Mean (s.d.) | 42.14 (2.72) | 42.27 (2.71) | 42.78 (2.63) | 42.48 (2.96) |
| Haptoglobin (g l−1) | ||||
| Mean (s.d.) | 1.13 (0.33) | 1.12 (0.32) | 1.07 (0.29) | 1.10 (0.31) |
| Leukocytes (109/l) | ||||
| Mean (s.d.) | 6.76 (1.97) | 6.74 (2.06) | 6.59 (1.93) | 6.68 (1.95) |
Abbreviations: CRC=colorectal cancer; CRP=C-reactive protein; TNM=tumour node metastasis.
a
CRP>10 mg l.